China Pharma Holdings Inc (China Pharma) is engaged in the development, manufacture, and marketing of pharmaceutical products for human use, targeting high-incidence and high-mortality diseases and medical conditions. China Pharma, through its subsidiary, Hainan Helpson Medical & Biotechnology Co Ltd, manufactures a wide range of pharmaceutical products, including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company's product portfolio includes basic generic drugs, first-to-market generic drugs, and modern Traditional Chinese Medicines (TCMs). In addition to pharmaceutical products, the company also manufactures healthcare products and protective products such as masks and sanitizers. The company categorizes its products into four categories namely CNS Cerebral & Cardio Vascular; Anti-Viral/ Infection & Respiratory; Digestive Diseases and Other. As of December 31, 2024, the company manufactured 19 pharmaceutical products for various diseases and indications and owned 15 registered trademarks.

The company’s R&D activities focus on developing both the first generic drugs and innovative drugs. It has been actively working to meet medical needs by sticking to a market-oriented approach and continuously improving the effectiveness and ease of use of its drugs. The company's recent R&D work is mainly aimed at promoting the consistent evaluation of several major products already on the market, as well as the continued exploration of comprehensive health product categories. The company is also actively involved in developing both first generic and innovative drugs, targeting chronic diseases prevalent in China. China Pharma has recently acquired formulas for dry eye syndrome, chronic obstructive pulmonary disease, and a pharmaceutical composition for the treatment of psoriasis. China Pharma operates one R&D center, 15 registered trademarks, and has acquired several patents. The company has also formed strategic partnerships with more than 20 leading research institutes, independent laboratories, and clinic research arms in hospitals in China. In FY2024, the company spent US$0.28 million on its R&D activities, which grew 16.7% YoY.